February 21, 2014 - The plaintiff filed a notice of voluntary dismissal without prejudice.
September 18, 2013 - An investor in shares of Edwards Lifesciences Corporation (NYSE: EW) filed a lawsuit in the U.S. District Court for the Central District of California against Edwards Lifesciences Corporation over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between April 25, 2012 and April 23, 2013.

According to the complaint the plaintiff alleges, on behalf of all persons or entities who purchased or otherwise acquired securities of Edwards Lifesciences Corporation (NYSE: EW) between April 25, 2012 and April 23, 2013 , that Edwards Lifesciences Corporation and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing allegedly false and/or misleading statements and failed to disclose material facts related to the prospects, projected sales and adoption of the Company’s Edwards SAPIEN transcatheter aortic heart valve, including the related transfemoral and transapical delivery methods (“SAPIEN”), and related projections of financial performance for the Company’s operations.

Edwards Lifesciences Corporation reported that its annual Revenue rose from over $1.44 billion in 2010 to over $167 billion in 2011and its Net Income rose from $218.00 million in 2010 to $236.70 million in 2011.

Shares of Edwards Lifesciences Corporation (NYSE: EW) grew to as high as $109.75 per share on October 4, 2012.

However, the plaintiff alleges that the defendants allegedly knew but concealed from Edwards Lifesciences Corporation’s shareholders between April 25, 2012 and April 23, 2013 that adoption of SAPIEN was weaker than the Company claimed, due to concerns among physicians over the risks and complexity of the procedure for implanting the valve, that Edwards Lifesciences Corporation’s outlook for sales and earnings per share was significantly weaker than the optimistic guidance defendants offered to investors, and that as a result, defendants lacked a reasonable basis for the statements made concerning Edwards Lifesciences Corporation’s operations, forecasts and outlook.

On October 8, 2012, Edwards Lifesciences Corporation announced its preliminary third quarter 2012 sales. Edwards Lifesciences Corporation estimates total sales of $448 million for the third quarter that ended on September 30, 2012, which is lower than Edwards Lifesciences Corporation’s guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012.

Then on April, 23, 2013, Edwards Lifesciences Corporation reported its first quarter results. The plaintiff says that Edwards Lifesciences Corporation disclosed that approximately 20 candidate hospitals had postponed SAPIEN training, that there was substantially no backlog of patients awaiting SAPIEN implants, and that the Company’s financial results had been and would likely continue to be weaker than estimates.

Shares of Edwards Lifesciences Corporation(NYSE: EW) dropped from almost $110 in October 2012 to as low as $62.54 per share in May 2013.

On September 19, 2013, Edwards Lifesciences Corporation (NYSE: EW) shares closed at $70.71 per share.